A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin

← catalyst calendar

NCT06625307

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

31actual

Sites

Country

Netherlands

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-10-03

actual

When the study began enrolling

Primary completion

2025-05-04

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-05-04

actual

The whole study's end, after follow-up

First posted

2024-10-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Healthy Volunteers
Heart Failure

Interventions

Drug: NNC0537-1482
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Number of treatment emergent adverse events (TEAE) in cohorts 1 and 2

measured From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 15

Number of treatment emergent adverse events (TEAE) in cohort 3

measured From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 22

Number of treatment emergent adverse events (TEAE) in cohorts 4, 5 and 6

measured From pre-dose on Day 1 until completion of the End of study visit (V10) at Day 40

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed